Hospital
Children's Hospital at Mission
Children's Hospital at Mission was paid $1.44M by Medicaid between Jan 2018 and Nov 2024, across 124 billing codes. Its largest line is 0450, Emergency room services — 35% of everything it billed.
33Billing provider infoCHILDREN'S HOSPITAL AT MISSION
MISSION VIEJO, CA 92691
MISSION VIEJO, CA 92691
33aNPI1699868398assigned 10/02/2006
33bProvider typeChildren's Hospital
28Total paid$1.44M
24GClaims138,702
24DCodes billed124
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Children's Hospital providers in California
Rank by total paid#9 of 17
Median peer was paid$1.44M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,143 | $62K | |
| 2019 | 25,049 | $102K | |
| 2020 | 13,068 | $53K | |
| 2021 | 14,295 | $66K | |
| 2022 | 17,628 | $127K | |
| 2023 | 24,615 | $306K | |
| 2024incomplete | 21,904 | $729K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 35% | 26,561 | 24,584 | $507K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 6.9% | 1,214 | 1,213 | $100K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.7% | 1,537 | 1,476 | $68K |
| 95782 | 4.4% | 316 | 313 | $64K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.7% | 2,763 | 2,642 | $53K |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 3.2% | 4,289 | 3,768 | $47K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.1% | 2,898 | 2,649 | $45K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 2.9% | 2,159 | 2,020 | $42K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.8% | 2,063 | 1,824 | $41K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.6% | 1,887 | 1,674 | $38K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.6% | 318 | 294 | $38K |
| 99199 | Unlisted special service, procedure or report | 2.4% | 1,040 | 931 | $34K |
112 more codes
| J3490 | Unclassified drugs | 2.1% | 13,230 | $30K |
| 71045 | Radiologic examination, chest; single view | 2.1% | 4,029 | $30K |
| 95716 | 1.9% | 55 | $27K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.9% | 2,359 | $27K |
| 80053 | Comprehensive metabolic panel | 1.7% | 5,087 | $24K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 6,538 | $17K |
| 0160 | 1.1% | 450 | $16K | |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 2,591 | $15K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 654 | $9K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 69 | $8K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 269 | $8K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,178 | $8K |
| 73110 | <1% | 960 | $8K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,223 | $8K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 69 | $7K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,964 | $7K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,265 | $7K |
| 73610 | <1% | 924 | $7K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 546 | $6K |
| 74018 | <1% | 910 | $6K | |
| 73630 | <1% | 664 | $6K | |
| 83690 | <1% | 2,366 | $5K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,718 | $5K |
| 81001 | <1% | 5,196 | $5K | |
| 99283 | Emergency room visit (moderate) | <1% | 68 | $4K |
| 87420 | <1% | 1,712 | $4K | |
| 84703 | <1% | 1,590 | $4K | |
| 84145 | <1% | 357 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,792 | $3K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,801 | $3K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 45 | $3K |
| Z7502 | <1% | 77 | $3K | |
| 73080 | <1% | 287 | $3K | |
| 73562 | <1% | 291 | $3K | |
| 86140 | <1% | 1,699 | $3K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 136 | $3K |
| 87807 | <1% | 1,794 | $3K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 119 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 468 | $2K |
| 87081 | <1% | 1,287 | $2K | |
| 87040 | <1% | 343 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 756 | $2K |
| 76770 | <1% | 112 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 185 | $2K |
| 87631 | <1% | 75 | $996.69 | |
| 73090 | <1% | 196 | $981.97 | |
| 0360 | <1% | 277 | $964.73 | |
| 73130 | <1% | 179 | $954.05 | |
| 0270 | <1% | 7,190 | $876.70 | |
| 80143 | <1% | 28 | $674.27 | |
| 81003 | <1% | 2,232 | $605.41 | |
| 0710 | <1% | 492 | $578.03 | |
| 87430 | <1% | 311 | $565.22 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 137 | $457.60 |
| 80179 | <1% | 15 | $456.62 | |
| 80299 | <1% | 136 | $398.54 | |
| 81025 | <1% | 237 | $395.75 | |
| 12011 | <1% | 79 | $382.54 | |
| J2704 | Injection, propofol, 10 mg | <1% | 215 | $367.77 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 1,379 | $364.06 |
| 82150 | <1% | 395 | $342.82 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 188 | $313.75 |
| 83605 | <1% | 42 | $254.49 | |
| 73030 | <1% | 45 | $247.40 | |
| 83735 | <1% | 162 | $212.26 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 129 | $209.28 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 114 | $196.29 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 87 | $187.28 |
| 0250 | <1% | 1,067 | $181.57 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 73 | $181.48 |
| 73140 | <1% | 61 | $173.77 | |
| 84702 | <1% | 43 | $170.49 | |
| 86141 | <1% | 122 | $170.05 | |
| 73590 | <1% | 13 | $140.61 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 130 | $125.34 |
| 72170 | <1% | 17 | $106.72 | |
| 88304 | <1% | 30 | $104.87 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 13 | $87.64 |
| 29125 | <1% | 115 | $75.00 | |
| 85027 | <1% | 27 | $72.84 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 34 | $71.19 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 53 | $69.74 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 367 | $54.82 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 68 | $53.54 |
| 82550 | <1% | 15 | $46.70 | |
| 86308 | <1% | 27 | $43.83 | |
| 84484 | <1% | 13 | $37.96 | |
| 87077 | <1% | 12 | $37.31 | |
| 71010 | <1% | 57 | $36.78 | |
| 73502 | <1% | 13 | $36.69 | |
| 29515 | <1% | 24 | $30.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 144 | $29.41 |
| 71020 | <1% | 113 | $24.97 | |
| 87899 | <1% | 32 | $16.57 | |
| 87045 | <1% | 17 | $13.32 | |
| 80047 | <1% | 13 | $13.08 | |
| 80076 | <1% | 28 | $11.88 | |
| 85007 | <1% | 13 | $8.68 | |
| 85652 | <1% | 15 | $7.72 | |
| 87205 | <1% | 18 | $5.54 | |
| 87046 | <1% | 17 | $4.18 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 16 | $2.12 |
| 85014 | <1% | 12 | $2.11 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 18 | $2.10 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 593 | $0.15 |
| 94664 | 0% | 29 | $0.00 | |
| 0320 | 0% | 121 | $0.00 | |
| 93976 | 0% | 13 | $0.00 | |
| 0300 | 0% | 249 | $0.00 | |
| 0636 | 0% | 62 | $0.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 121 | $0.00 |
| 0301 | 0% | 46 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialULI, JAMES (EXECUTIVE VP & CFO)
| Provider | Location | Paid |
|---|---|---|
| Rady Children's Hospital San Diego | Escondido, CA | $7.32M |
| Rady Children's Hospital San Diego | San Diego, CA | $566K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.